Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy: The Next Step in the Treatment of Renal Cell Carcinoma

Adaptive MR-guided radiotherapy (MRgRT) is a new treatment paradigm and its role as a non-invasive treatment option for renal cell carcinoma is evolving. The early clinical experience to date shows that real-time plan adaptation based on the daily MRI anatomy can lead to improved target coverage and normal tissue sparing. Continued technological innovations will further mitigate the challenges of organ motion and enable more advanced treatment adaptation, and potentially lead to enhanced oncologic outcomes and preservation of renal function. Future applications look promising to make a positive clinical impact and further the personalization of radiotherapy in the management of renal cell carcinoma.

Automated summary

Adaptive MR-guided radiotherapy is emerging as a non-invasive treatment option for renal cell carcinoma, with real-time plan adaptation based on daily MRI anatomy showing improved target coverage and normal tissue sparing. Continued technological innovations are expected to address organ motion challenges and enhance oncologic outcomes, promising a positive clinical impact in the management of renal cell carcinoma.